New hope for tough ovarian cancers: experimental combo therapy enters testing
NCT ID NCT07311577
Summary
This study is testing whether adding a newer targeted drug called disitamab vedotin to standard chemotherapy and bevacizumab works better for certain high-risk ovarian cancers. It will involve 43 patients whose cancer has specific features (HER2-positive and HRD-negative) and is considered high-risk. The goal is to see if this combination can better control the cancer and keep it from growing back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Cancer Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210000, China
-
Jiangsu Cancer Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.